GlassScriptPhysician profile
Sam Vang
NPI 1447975875
$1,054.88
in general payments reported to CMS, 2019-2025
14 companies · $415 in 2025
The $415 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $312 · 2024: $328 · 2025: $415.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,055.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,054.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $216.56 | 2025 | Wegovy, Ozempic |
| Abbvie INC. | $175.31 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.04 | 2023 | Jardiance |
| Gilead Sciences, INC. | $131.55 | 2023-2024 | |
| Phathom Pharmaceuticals, INC. | $120.07 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $62.36 | 2024-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Viiv Healthcare Company | $52.40 | 2023-2024 | Apretude, Dovato |
| Bayer Healthcare Pharmaceuticals INC. | $34.04 | 2024 | |
| Lilly USA, LLC | $28.92 | 2023-2025 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $23.58 | 2024 | Airsupra |
| Ultragenyx Pharmaceutical INC. | $20.43 | 2023 | |
| Verrica Pharmaceuticals INC. | $20.03 | 2024 | Ycanth |
| Hologic Sales and Service, LLC | $19.97 | 2025 | Aptima |
| Kyowa Kirin, INC. | $16.62 | 2023 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sam Vang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.